Skip to main content

Bristol-Myers Squibb Company (BMY) Stock Analysis

Breakout setup

HoldHigh Confidence

Healthcare · Drug Manufacturers - General

Earnings in 0 days (2026-04-30). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Hold if already holding. Not a fresh buy at $60.22, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: United States (69.0%); Analyst target reached - limited upside remaining.

Bristol-Myers Squibb discovers, develops, and markets innovative medicines across oncology, hematology, immunology, cardiovascular, and neuroscience, operating in a single segment. It sells products globally with 69% of revenues from the United States in 2025, generating $48.2... Read more

$60.22+7.3% A.UpsideScore 5.5/10#9 of 16 Drug Manufacturers - General
Entry $55.32(R/R-minimum solve)Stop $52.62Target $59.37(resistance)A.R:R -1.2:1Setup A.R:R 1.5:1
Analyst target$63.04+4.7%25 analysts
$59.37our TP
$60.22price
$63.04mean
$40
$75

Hold if already holding. Not a fresh buy at $60.22, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: United States (69.0%); Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 58, MACD bullish. Downgraded from BUY WAIT — price $60.22 has reached target $59.37. No upside to wait for. Score 5.5/10, high confidence.

Passes 4/7 gates (positive momentum, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: moderate.

Val7.1Qual7.5Grw2.8Mom5.2Sent5.3Ins5.0Peer4.8Tech3.7Risk7.35.5OVERALL

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Geographic: United States (69.0%)
Analyst target reached - limited upside remaining
Near 52-week high (4.2% away)

Key Metrics

P/E (TTM)16.6
P/E (Fwd)9.4
Mkt Cap$117.6B
EV/EBITDA8.0
Profit Mgn14.6%
ROE40.4%
Rev Growth1.3%
Beta0.27
Dividend4.38%
Rating analysts36

Quality Signals

Piotroski F7/9

Options Flow

P/C0.32bullish
IV40%normal
Max Pain$72+19.6% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHGeographicUnited States69%
    10-K Item 1: 'United States| 69 | %| | 71 | %| | 69 | %'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Revenue Growth
2.8
Low model confidence on this dimension (33%).

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Bollinger
0.5
Support Resistance
1.1
52w Position
9.4
GatesA.R:R -1.2=NEGATIVEEARNINGS PROXIMITY 0d<=7dMomentum 5.2<5.5 (soft — BUY_NOW allowed but watch)Momentum 5.2>=4.5Insider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARBreakoutSuitability: Moderate
RSI
58 · Neutral
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $57.22Resistance $60.58

Price Targets

$53
$55
$59
A.Upside-1.4%
A.R:R-1.2:1
Setup A.R:R (at entry)1.5:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Target reached (-5.8% upside)
! Earnings in 0 days - binary event risk
! Negative risk/reward — downside exceeds upside

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-04-30 (0d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is BMY stock a buy right now?

Hold if already holding. Not a fresh buy at $60.22, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: United States (69.0%); Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 58, MACD bullish. Downgraded from BUY WAIT — price $60.22 has reached target $59.37. No upside to wait for. Target $59.37 (-1.4%), stop $52.62 (−14.4%), A.R:R -1.2:1. Score 5.5/10, high confidence.

What is the BMY stock price target?

Take-profit target: $59.37 (+7.3% upside). Target $59.37 (-1.4%), stop $52.62 (−14.4%), A.R:R -1.2:1. Stop-loss: $52.62.

What are the risks of investing in BMY?

Concentration risk — Geographic: United States (69.0%); Analyst target reached - limited upside remaining; Near 52-week high (4.2% away).

Is BMY overvalued or undervalued?

Bristol-Myers Squibb Company trades at a P/E of 16.6 (forward 9.4). TrendMatrix value score: 7.1/10. Verdict: Hold.

What do analysts say about BMY?

36 analysts cover BMY with a consensus score of 3.5/5. Average price target: $63.

What does Bristol-Myers Squibb Company do?Bristol-Myers Squibb discovers, develops, and markets innovative medicines across oncology, hematology, immunology,...

Bristol-Myers Squibb discovers, develops, and markets innovative medicines across oncology, hematology, immunology, cardiovascular, and neuroscience, operating in a single segment. It sells products globally with 69% of revenues from the United States in 2025, generating $48.2 billion in total revenues.

Related stocks: LLY (Eli Lilly and Company) · GSK (GSK plc) · GILD (Gilead Sciences, Inc.) · AMGN (Amgen Inc.) · BIIB (Biogen Inc.)